Ποια είναι η τιμή για Theradiag S.A. (ALTER)

Η τιμή για Theradiag S.A. (ALTER) είναι $1.38

Ποια είναι η κεφαλαιοποίηση αγοράς για Theradiag S.A. (ALTER)

Η κεφαλαιοποίηση αγοράς για Theradiag S.A. (ALTER) είναι $12.52M

Theradiag S.A. (ALTER) Τιμή και Κεφαλαιοποίηση Αγοράς

Theradiag S.A. specializes in the creation, production, and marketing of in-vitro diagnostic solutions. Its product line encompasses reagents for autoimmune conditions, IMMUNO-TROL — a comprehensive quality control tool with multiple parameters — and various instruments for testing both autoimmune disorders and infectious diseases. Among its unique offerings are the SQA-V system, engineered for semen analysis, and V-Sperm, a specialized application for digitally uploading and viewing sample results, including pictures and video recordings. The company's advanced instrumentation includes Theralis, which integrates multiplex FIDIS immunofluorescence with ELISA capabilities; Theralis µ, designed as a suitable solution for mid-sized laboratories; and the FIDIS platform, utilized for diverse laboratory analyses. Furthermore, Theradiag provides therapeutic drug monitoring services aimed at managing chronic inflammatory conditions. It also offers LISA tracker, an essential device for overseeing biotherapies, alongside both ELISA and rapid serological tests for SARS-CoV-2. Founded in 1986, Theradiag S.A. is based in Marne La Vallee, France.

Η τιμή για ALTER	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$603,745 $12.52M	NVDA	$5.460T	+43,620,471.63%
$496,416 $12.52M	AAPL	$4.489T	+35,865,989.23%
$457,871 $12.52M	GOOG	$4.141T	+33,081,112.09%
$394,584 $12.52M	MSFT	$3.569T	+28,508,598.98%
$309,387 $12.52M	AMZN	$2.798T	+22,353,107.06%

Η τιμή για ALTER

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$603,745 $12.52M